Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Patients at Increased Risk for the Development of Ventilator-associated Pneumonia in the Intensive Care Unit (BIOPAVIR)

University Hospital Center (CHU) Dijon Bourgogne

Status: Completed

Conditions: Biofilm Formation; Structural and Microbiological Characterization of Endotracheal Tube Biofilm; Ventilator-associated Pneumonia (VAP)

Treatments: Biological: microbiological characterization

Study type: Observational

Funder types: Other

Identifiers

NCT04926493

QUENOT-Maldiney 2021

Details and patient eligibility

About

Ventilator-associated pneumonia (VAP) remains the most frequent healthcare-associated infection (HAI) in the intensive care unit (ICU) and one of the most critical risk factors associated with both significant morbidity as well as mortality. Although VAP treatment relies on early and appropriate antimicrobial therapy, several preventive measures have been described in the literature in order to limit its incidence and clinical impact in the ICU. Among these, preventing biofilm formation on the inner surface of the endotracheal tube appears to hold promise. Yet there is a lack of clinical relevant data documenting a causal relation between biofilm formation and VAP. Designed to overcome this critical limitation, the BIOPAVIR study intends to provide a better structural and microbiological characterization of endotracheal tube biofilm in critically ill patients at increased risk for the development of VAP in ICU during COVID-19 pandemic.

Enrollment: 61 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient > 18 years of age with mechanical ventilation for >2 calendar days

Exclusion criteria

• inability to collect or dispatch the endotracheal tube for proper characterization within 24 hours post-extubation

Trial design

61 participants in 1 patient group

BIOPAVIR Cohort

Description:

Critically ill patient \> 18 years of age with mechanical ventilation for \>2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.

Treatment:

Biological: microbiological characterization